■近年来,Psilocybin和相关的色胺已成为抑郁症的潜在治疗方法。对这些作用机制的研究历来集中在这些药物对神经过程的直接作用上。然而,除了这种神经效应,外周生理学的改变也可能有助于其治疗效果。特别是,对于其他药物的抗抑郁功效,存在肠道微生物组介导的途径的大量支持,但是以前没有研究确定色胺对微生物群的影响。
■为了解决这个问题,在这项初步研究中,雄性LongEvans大鼠接受不同剂量的口服psilocybin(0.2或2mg/kg)治疗,去甲细胞素(0.25或2.52毫克/千克),在暴露后1周和3周收集或媒介物及其粪便样品,用于使用整合的16S核糖体DNA测序进行微生物组分析,以确定肠道微生物组组成。
■我们发现,尽管用psilocybin和norbaebocystin治疗都不会显著影响整体微生物组多样性,它确实引起了门水平细菌丰度的显著剂量和时间依赖性变化,包括Verrucomicrobia和放线菌的增加,以及变形杆菌的减少。
■这些初步发现支持了psilocybin和其他色胺可能以剂量和时间依赖性方式作用于肠道微生物组的观点。潜在的确定他们的抗抑郁活性的一个新的外周机制。这项初步研究的结果还表明,作为一种潜在的抗抑郁药,去甲细胞素可能需要进一步研究。考虑到其与裸盖素的作用相似。
UNASSIGNED: Psilocybin and related tryptamines have come into the spotlight in recent years as potential therapeutics for depression. Research on the mechanisms of these effects has historically focused on the direct effects of these drugs on neural processes. However, in addition to such neural effects, alterations in peripheral physiology may also contribute to their therapeutic effects. In particular, substantial support exists for a gut microbiome-mediated pathway for the antidepressant efficacy of other drug classes, but no prior studies have determined the effects of tryptamines on microbiota.
UNASSIGNED: To address this gap, in this preliminary study, male Long Evans rats were treated with varying dosages of oral psilocybin (0.2 or 2 mg/kg), norbaeocystin (0.25 or 2.52 mg/kg), or vehicle and their fecal samples were collected 1 week and 3 weeks after exposure for microbiome analysis using integrated 16S ribosomal DNA sequencing to determine gut microbiome composition.
UNASSIGNED: We found that although treatment with neither psilocybin nor norbaeocystin significantly affected overall microbiome diversity, it did cause significant dose- and time-dependent changes in bacterial abundance at the phylum level, including increases in Verrucomicrobia and Actinobacteria, and decreases in Proteobacteria.
UNASSIGNED: These preliminary findings support the idea that psilocybin and other tryptamines may act on the gut microbiome in a dose- and time-dependent manner, potentially identifying a novel peripheral mechanism for their antidepressant activity. The results from this preliminary study also suggest that norbaeocystin may warrant further investigation as a potential antidepressant, given the similarity of its effects to psilocybin.